Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
TGF beta 2
Introduction
Transforming growth factor-beta 2 (TGF-β2) is a secreted protein known as a cytokine that performs many cellular functions and has a vital role during embryonic development (alternative names: Glioblastoma-derived T-cell suppressor factor, G-TSF, BSC-1 cell growth inhibitor, Polyergin, Cetermin). It is an extracellular glycosylated protein. It is known to suppress the effects of interleukin dependent T-cell tumors. There are two named isoforms of this protein, created by alternative splicing of the same gene.
Further reading
- Clark DA, Coker R (1998). “Transforming growth factor-beta (TGF-beta)”. Int. J. Biochem. Cell Biol. 30 (3): 293–8. doi:10.1016/S1357-2725(97)00128-3. PMID 9611771.
- Wick W, Platten M, Weller M (2002). “Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta”. J. Neurooncol. 53 (2): 177–85. doi:10.1023/A:1012209518843. PMID 11716069.
- Bissell DM (2002). “Chronic liver injury, TGF-beta, and cancer”. Experimental & Molecular Medicine. 33 (4): 179–90. doi:10.1038/emm.2001.31. PMID 11795478.
- Kalluri R, Neilson EG (2004). “Epithelial-mesenchymal transition and its implications for fibrosis”. J. Clin. Invest. 112 (12): 1776–84. doi:10.1172/JCI20530. PMC 297008. PMID 14679171.
- Daopin S, Piez KA, Ogawa Y, Davies DR (1992). “Crystal structure of transforming growth factor-beta 2: an unusual fold for the superfamily”. Science. 257 (5068): 369–73. doi:10.1126/science.1631557. PMID 1631557.
- Schlunegger MP, Grütter MG (1992). “An unusual feature revealed by the crystal structure at 2.2 A resolution of human transforming growth factor-beta 2”. Nature. 358 (6385): 430–4. doi:10.1038/358430a0. PMID 1641027.
- Noma T, Glick AB, Geiser AG, et al. (1992). “Molecular cloning and structure of the human transforming growth factor-beta 2 gene promoter”. Growth Factors. 4 (4): 247–55. doi:10.3109/08977199109043910. PMID 1764261.
- Bodmer S, Podlisny MB, Selkoe DJ, et al. (1990). “Transforming growth factor-beta bound to soluble derivatives of the beta amyloid precursor protein of Alzheimer’s disease”. Biochem. Biophys. Res. Commun. 171 (2): 890–7. doi:10.1016/0006-291X(90)91229-L. PMID 2119582.
- Webb NR, Madisen L, Rose TM, Purchio AF (1989). “Structural and sequence analysis of TGF-beta 2 cDNA clones predicts two different precursor proteins produced by alternative mRNA splicing”. DNA. 7 (7): 493–7. doi:10.1089/dna.1.1988.7.493. PMID 2850146.
- Madisen L, Webb NR, Rose TM, et al. (1988). “Transforming growth factor-beta 2: cDNA cloning and sequence analysis”. DNA. 7 (1): 1–8. doi:10.1089/dna.1988.7.1. PMID 3162414.
- Barton DE, Foellmer BE, Du J, et al. (1989). “Chromosomal mapping of genes for transforming growth factors beta 2 and beta 3 in man and mouse: dispersion of TGF-beta gene family”. Oncogene Res. 3 (4): 323–31. PMID 3226728.
- de Martin R, Haendler B, Hofer-Warbinek R, et al. (1988). “Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family”. EMBO J. 6 (12): 3673–7. PMC 553836. PMID 3322813.
- Marquardt H, Lioubin MN, Ikeda T (1987). “Complete amino acid sequence of human transforming growth factor type beta 2”. J. Biol. Chem. 262 (25): 12127–31. PMID 3476488.
- Philip A, Bostedt L, Stigbrand T, O’Connor-McCourt MD (1994). “Binding of transforming growth factor-beta (TGF-beta) to pregnancy zone protein (PZP). Comparison to the TGF-beta-alpha 2-macroglobulin interaction”. Eur. J. Biochem. 221 (2): 687–93. doi:10.1111/j.1432-1033.1994.tb18781.x. PMID 7513640.
- Lin HY, Moustakas A, Knaus P, et al. (1995). “The soluble exoplasmic domain of the type II transforming growth factor (TGF)-beta receptor. A heterogeneously glycosylated protein with high affinity and selectivity for TGF-beta ligands”. J. Biol. Chem. 270 (6): 2747–54. doi:10.1074/jbc.270.6.2747. PMID 7852346.
- Hildebrand A, RomarÃs M, Rasmussen LM, et al. (1994). “Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta”. Biochem. J. 302. ( Pt 2): 527–34. doi:10.1042/bj3020527. PMC 1137259. PMID 8093006.
- López-Casillas F, Payne HM, Andres JL, Massagué J (1994). “Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites”. J. Cell Biol. 124 (4): 557–68. doi:10.1083/jcb.124.4.557. PMC 2119924. PMID 8106553.
- Fromigué O, Marie PJ, Lomri A (1998). “Bone morphogenetic protein-2 and transforming growth factor-beta2 interact to modulate human bone marrow stromal cell proliferation and differentiation”. J. Cell. Biochem. 68 (4): 411–26. doi:10.1002/(SICI)1097-4644(19980315)68:4<411::AID-JCB2>3.0.CO;2-T. PMID 9493905.
- Mori T, Kawara S, Shinozaki M, et al. (1999). “Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: A mouse fibrosis model”. J. Cell. Physiol. 181 (1): 153–9. doi:10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K. PMID 10457363.